Attovia Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Attovia Therapeutics, Inc. (ATTO) reported Debt Securities, Available-for-sale, Unrealized Loss of $87.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-02.
Financial Statements › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2026-09-02
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|
| 2026-06-30 | $87.00K 10-Q · filed 2026-09-02 | |
| 2025-12-31 | $1.00K 10-Q · filed 2026-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |